Laboratory Reference Grade Compounds

PE-22-28

RUO In-VitroLyophilized Powder≥99% Reference Standard
Protocol SOP↓
₱2,430.00
In Stock · Dispatches 24h
Net Content5MG
InclusionVial + BAC Water
Volume Discounts:Up to 20% OFF
1
SOPReconstitution Telemetry (5MG)
Diluent:mL
Concentration5.00 mg/mLin 1.0mL BAC
Standard Dose100 mcg – 200 mcg dailySyringe: 4.0 units (0.04 mL)
Scale (1 Unit)50 mcgper 0.01 mL (U-100)
✓ Includes 10mL Bacteriostatic Water USPMonograph SOP →
PE-22-285MG · Vial + BAC Water
₱2,430.00
1
Technical Specification & Protocol Dossier

Analytical Standards & Laboratory Handling

Verified laboratory protocols, reconstitution parameters, and handling guidelines.

P

Pharmacological Profile & Mechanism of Action

Research Monograph

What it is: PE-22-28 is a synthetic heptapeptide derivative of spadin (a natural propeptide directed against sortilin) specifically engineered as a selective, high-affinity blocker of the two-pore domain potassium channel TREK-1 (K2P2.1).

How it works: By selectively blocking TREK-1 channels in hippocampal neurons, PE-22-28 enhances neuronal excitability, promotes rapid synaptogenesis, and stimulates immediate CREB phosphorylation and BDNF transcription. Unlike conventional monoaminergic modulators, PE-22-28 exerts rapid neurotrophic and behavioral actions within hours rather than weeks.

Why researchers study it: Researched for rapid-onset neuroplasticity, mood elevation, resistance to chronic stress, reversing hippocampal dendritic atrophy, and cognitive preservation in neurodegenerative models.

Compound & Molecular Specifications

Certificate of Analysis Standards
Target CategoryCognitive & Neuroprotective
Intended ApplicationLaboratory & In-Vitro Research Only (RUO)
Physical StateLyophilized Solid Powder
CAS Registry Number1374526-08-3
PubChem CID137088487↗
Molecular Weight740.9 g/mol
Purity Specification≥99.0% (HPLC-grade)
Net Content Options5MG
Inclusion PackagesVial Only, Vial + BAC Water, Analytical Lab Set
Peptide Sequence / FormulaGly-Lys-Leu-Pro-Arg-Ala-Ser (GKLPRAS)